11 completed, 4 unknown, 1 terminated. 3 Phase 2, 3 Phase 4, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Unknown 2 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Retinal Vasculitis: new trials by email Literature Review of Retinal Vasculitis trials Research Report on Retinal Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study aflibercept 2mg - Retinal Vasculitis | Completed | Regeneron Pharmaceuticals | 290000 | 2025-07-15 | 2025-10-10 | |
| A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) aflibercept 2 mg - Retinal Vasculitis | Completed | Regeneron Pharmaceuticals | 550000 | 2025-07-01 | 2025-10-29 | |
| Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy Intraoperative Fluorescein Angiography - Vascular Retinopathy of Left Eye (Disorder), Vascular Retinopathy of Right Eye (Disorder) | Not applicable | Unknown | Jie Zhong | 80 | 2024-04-18 | 2024-04-03 |
| Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion Brolucizumab - Intraocular Inflammation, Retinal Vascular Occlusion | Completed | Novartis Pharmaceuticals | 198 | 2021-08-23 | 2022-12-20 | |
| Six-months Versus Nine-months ATT for Ocular TB Anti-Tuberculosis Treatment - Tuberculosis (TB), Uveitis | Phase 4 | Completed | L.V. Prasad Eye Institute | 58 | 2020-01-01 | 2024-09-26 |
| Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography Retinal Vasculitis, Behcet Syndrome | Completed | Assiut University | 30 | 2018-03-01 | 2021-01-13 | |
| Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis H.P. ACTHAR GEL - Uveitis, Posterior, Vasculitis Retinal | Phase 4 | Unknown | Ocular Immunology and Uveitis Foundation | 40 | 2017-03-22 | 2019-09-12 |
| Optical Coherence Tomography (OCT) in Retinal Vasculitis Retinal Vasculitis | Completed | Oregon Health and Science University | 12 | 2014-01-01 | 2024-02-12 | |
| Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Etanercept, Methotrexate, Prednisolone - Behcet Syndrome, Uveal Disease | Not applicable | Unknown | Tehran University of Medical Sciences | 80 | 2010-10-01 | 2010-11-22 |
| The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease methylorednisolone, dextrose water 5% - Behcet's Disease | Phase 4 | Unknown | Tehran University of Medical Sciences | 34 | 2010-02-01 | 2011-03-02 |
| Safety and Efficacy of AIN457 in Noninfectious Uveitis AIN457, AIN 457 - Non-infectious Uveitis | Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2008-06-01 | 2017-07-17 |
| Stem Cell Transplantation in Ocular Lesions of Behcet's Disease Autologous Stem Cell Transplantation - Retinitis, Behcet's Syndrome | Phase 1 | Terminated | Tehran University of Medical Sciences | 5 | 2007-12-01 | 2015-11-10 |
| Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease Rituximab, Cytotoxic Combination - Behcet's Syndrome | Phase 2 | Completed | Tehran University of Medical Sciences | 20 | 2006-04-01 | 2008-04-30 |
| Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) Cyclosporin A, Interferon-alpha2a - Behcet's Disease, Panuveitis | Phase 3 | Completed | University Hospital Tuebingen | 37 | 2004-11-01 | 2018-05-17 |
| Biological Markers in Retinal Vasculitis Retinal Vasculitis | Completed | National Eye Institute (NEI) | 200 | 2002-12-06 | 2017-07-02 | |
| HAT in Eye Complications of Behcet's Disease Daclizumab - Behcet's Syndrome, Retinal Disease | Phase 2 | Completed | National Eye Institute (NEI) | 26 | 1999-07-01 | 2008-03-04 |
Behcet Syndrome (8) · Uveitis (5) · Uveitis, Posterior (4) · Diabetic Retinopathy (3) · Panuveitis (2) · Birdshot Chorioretinopathy (1) · Choroiditis (1) · Diabetes Mellitus, Insulin-Dependent, 10 (1) · Multifocal Choroiditis (1) · Ophthalmia, Sympathetic (1) · Papilledema (1) · Retinal Diseases (1) · Retinal Vein Occlusion (1) · Retinitis (1)
Cardiovascular Diseases (16) · Eye Diseases (16) · Vascular Diseases (16) · Retinal Diseases (15) · Vasculitis (15) · Uveal Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Hereditary Autoinflammatory Diseases (8) · Mouth Diseases (8) · Panuveitis (8) · Skin Diseases (8) · Skin Diseases, Genetic (8) · Skin Diseases, Vascular (8) · Skin and Connective Tissue Diseases (8)
aflibercept (2) · Cyclophosphamide (1) · Cyclosporine (1) · Daclizumab (1) · Etanercept (1) · Interferon alpha-2 (1) · Methotrexate (1) · Prednisolone (1) · Rituximab (1) · brolucizumab (1) · secukinumab (1)
Tehran University of Medical Sciences (4) · National Eye Institute (NEI) (2) · Novartis Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · Assiut University (1) · Jie Zhong (1) · L.V. Prasad Eye Institute (1) · Ocular Immunology and Uveitis Foundation (1) · Oregon Health and Science University (1) · University Hospital Tuebingen (1)
United States (7) · Iran (4) · Germany (2) · Burma (1) · Egypt (1) · India (1) · Switzerland (1) · Thailand (1)
Fereydoun Davatchi, MD (3) · Hormoz Shams, MD (2) · Bahar Sadeghi, MD (1) · Behrouz Nikbin, MD (1) · Cheyda Chams-Davatchi, MD (1) · Farhad Shahram, MD (1) · Farhad Shahram, Professor (1) · Ina Koetter, MD (1) · Mozhgan Rezaipoor, MD (1) · Phoebe Lin, MD, PhD (1)